Department of Radiation Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, 350014, Fujian, China.
Fujian Medical University, Fujian, 350122, China.
BMC Cancer. 2019 Oct 30;19(1):1023. doi: 10.1186/s12885-019-6141-z.
The aim of the present study was to assess the efficacy of postoperative chemoradiotherapy (POCRT) following surgery in non-small-cell lung cancer patients with N2 lymph node metastasis (N2-NSCLC).
The clinical data of patients with N2-NSCLC treated with POCRT or postoperative chemotherapy (pCT) alone were retrospectively collected and reviewed. The overall survival (OS) rates were analyzed utilizing the Kaplan-Meier method and compared by the log-rank test. Cox regression analysis was used to determine factors significantly associated with survival. Propensity score matching (PSM) analysis was used to compensate for differences in baseline characteristics and OS was compared after matching.
Between 2004 and 2014, a total of 175 patients fulfilled the inclusion criteria, 60 of whom were treated with POCRT, while 115 were administered pCT. The 1, 3 and 5-year OS rates in the POCRT and pCT groups were 98.3 vs. 86.1%, 71.7 vs. 53.0% and 45.7 vs. 39.0%, respectively (P = 0.019). Compared with pCT, POCRT improved OS in patients with squamous cell subtype (P = 0.010), no lymphovascular invasion (P = 0.006), pN2a (P = 0.006) or total number of metastatic lymph nodes ≤7 (P = 0.016). After PSM, these survival differences between POCRT and pCT remained significant in patients with squamous cell lung cancer (P = 0.010).
POCRT following complete resection may be beneficial for patients with squamous cell lung cancer, particularly those with limited nodal involvement.
本研究旨在评估非小细胞肺癌 N2 淋巴结转移(N2-NSCLC)患者手术后同步放化疗(POCRT)的疗效。
回顾性收集并分析了接受 POCRT 或单纯术后化疗(pCT)治疗的 N2-NSCLC 患者的临床资料。采用 Kaplan-Meier 法分析总生存期(OS)率,并用对数秩检验进行比较。采用 Cox 回归分析确定与生存显著相关的因素。采用倾向评分匹配(PSM)分析来补偿基线特征的差异,并在匹配后比较 OS。
2004 年至 2014 年期间,共有 175 例患者符合纳入标准,其中 60 例接受 POCRT 治疗,115 例接受 pCT 治疗。POCRT 组和 pCT 组的 1、3 和 5 年 OS 率分别为 98.3%比 86.1%、71.7%比 53.0%和 45.7%比 39.0%(P=0.019)。与 pCT 相比,POCRT 改善了鳞状细胞亚型(P=0.010)、无血管淋巴管侵犯(P=0.006)、pN2a(P=0.006)或转移淋巴结总数≤7(P=0.016)患者的 OS。经 PSM 后,POCRT 与 pCT 在鳞状细胞肺癌患者中的生存差异仍有统计学意义(P=0.010)。
完全切除术后 POCRT 可能对鳞状细胞肺癌患者有益,特别是淋巴结受累有限的患者。